Fracasso Paula M, Blessing John A, Molpus Kelly L, Adler Lisa M, Sorosky Joel I, Rose Peter G
Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA.
Gynecol Oncol. 2006 Nov;103(2):523-6. doi: 10.1016/j.ygyno.2006.03.043. Epub 2006 May 19.
A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with advanced or recurrent endometrial cancer who had received one prior platinum therapy.
Eligible patients were to have measurable disease and one prior chemotherapy regimen which could include cisplatin or carboplatin. Oxaliplatin 130 mg/m2 was administered intravenously over 2 h. This treatment was repeated every 21 days until progression of disease or adverse effects prohibited further therapy.
Fifty-four patients were entered on study, of which 52 were eligible and 50 had had prior platinum therapy. The overall response rate was 13.5%, with three patients (5.8%) achieving a complete response and four patients (7.7%) achieving a partial response. Median duration of response was 10.9+ (range: 4.1-50.3+) months. Stable disease was reported in 15 (28.8%) patients, with an associated median duration of 5.4 (range: 2.2-19.6) months. Drug-related toxicities consisted of anemia, nausea and vomiting, and neurotoxicity.
Oxaliplatin at the dose and schedule employed has limited activity in patients with advanced or recurrent endometrial carcinoma who have had previous platinum therapy.
开展一项II期研究，以确定奥沙利铂治疗曾接受过一次铂类治疗的晚期或复发性子宫内膜癌患者的疗效。
符合条件的患者须有可测量病灶，且曾接受过一种化疗方案，该方案可包括顺铂或卡铂。奥沙利铂130mg/m²静脉滴注2小时。每21天重复此治疗，直至疾病进展或出现不良反应而禁止进一步治疗。
54例患者进入研究，其中52例符合条件，50例曾接受铂类治疗。总缓解率为13.5%，3例患者（5.8%）达到完全缓解，4例患者（7.7%）达到部分缓解。中位缓解持续时间为10.9+（范围：4.1 - 50.3+）个月。15例（28.8%）患者病情稳定，中位持续时间为5.4（范围：2.2 - 19.6）个月。药物相关毒性包括贫血、恶心呕吐和神经毒性。
对于曾接受过铂类治疗的晚期或复发性子宫内膜癌患者，采用的奥沙利铂剂量和给药方案活性有限。
